{
    "organizations": [],
    "uuid": "9f0005bc09ec06fd26135fbd0968947b31f91c52",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-basilea-pharmaceutica-licenses-lat/brief-basilea-pharmaceutica-licenses-late-stage-oncology-drug-candidate-derazantinib-idUSFWN1RU00L",
    "ord_in_thread": 0,
    "title": "BRIEF-Basilea Pharmaceutica Licenses Late-Stage Oncology Drug Candidate Derazantinib",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 17 (Reuters) - Basilea Pharmaceutica AG:\n* LICENSES LATE-STAGE ONCOLOGY DRUG CANDIDATE DERAZANTINIB FROM ARQULE Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-04-17T13:17:00.000+03:00",
    "crawled": "2018-04-18T18:24:18.036+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "basilea",
        "pharmaceutica",
        "ag",
        "license",
        "oncology",
        "drug",
        "candidate",
        "derazantinib",
        "arqule",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}